Novartis

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, November 4, 2021
Safety, Pancreatic cancer, Securities Act of 1933, Standard of care, Disease, Patient, Food, Terminology, SEC, Time, SOC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Novartis, Company, Economics, COVID-19, Form 10-K, Drug Quality and Security Act, Therapy, GLOBE, Ownership, Securities Exchange Act of 1934, Pharmaceutical industry

We are grateful to the patients and their families who are participating in all of the NIS793 clinical studies, stated Jim Neal, Chief Executive Officer of XOMA.

Key Points: 
  • We are grateful to the patients and their families who are participating in all of the NIS793 clinical studies, stated Jim Neal, Chief Executive Officer of XOMA.
  • More information about the NIS793 Phase 3 clinical study, NCT04935359, titled Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) can be found at ClinicalTrials.gov.
  • Under the terms of the 2015 anti-TGF development and commercialization agreement with Novartis, XOMA has the potential to earn up to $410 million in additional milestone payments.
  • As of the date of this press release, NIS793 and all assets in XOMAs milestone and royalty portfolio are investigational compounds.

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

Retrieved on: 
Thursday, November 4, 2021
Safety, Iterative method, Biotechnology, Securities Act of 1933, Silicon Valley Bank, Law, Patient, Insurance, Compugen, Food, Terminology, SEC, Amgen, Regulation of tobacco by the U.S. Food and Drug Administration, Time, Novartis, Company, TIGIT, Silicon, Economics, Board, COVID-19, Form 10-K, Health, Drug Quality and Security Act, G&A, Research, AstraZeneca, GLOBE, Ownership, Securities Exchange Act of 1934, Director, Board of directors, Pharmaceutical industry, Management, Ridesharing company, Air cargo

XOMA recorded total revenues of $0.9 million for the third quarter of 2021, compared with $0.6 million in the third quarter of 2020.

Key Points: 
  • XOMA recorded total revenues of $0.9 million for the third quarter of 2021, compared with $0.6 million in the third quarter of 2020.
  • General and administrative (G&A) expenses were $4.3 million for the third quarter of 2021, compared to $3.2 million for the third quarter of 2020.
  • In the third quarter of 2021, G&A expenses included $0.8 million in non-cash stock-based compensation expense, compared with $0.7 million in the third quarter of 2020.
  • Net loss for the third quarter of 2021 was $4.4 million, compared to net loss of $1.1 million for the third quarter of 2020.

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021

Retrieved on: 
Thursday, November 4, 2021
Annual general meeting, CD39, 2021 Essex County Council election, HCC, Cancer, Immunotherapy, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), Society, Corporation, CCR8, Risk, Annual report, Forward-looking statement, Novartis, Company, Society for Immunotherapy of Cancer, COVID-19, IL-27, PVRIG, CD73, IND, Oncology, Drug discovery, R, Research, G&A, GSK, Net, Bevacizumab, GLOBE, SITC, European Society for Medical Oncology, GlaxoSmithKline, Surface, Tumor microenvironment, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticipated near-term milestones.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticipated near-term milestones.
  • Third Quarter and Subsequent Corporate Highlights:
    On November 2, 2021, Surface announced that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place November 10-14, 2021, in Washington D.C. and virtually.
  • On July 8, 2021, Surface announced the appointment of Denice Torres to its board of directors as lead independent director.
  • Data update for SRF617 anticipated at the European Society for Medical Oncology Immuno-Oncology Congress taking place December 8-11, 2021.

Former Executive of Danone, Kraft and IAC Joins Organic Garage’s Future of Cheese as Strategic Advisor

Retrieved on: 
Thursday, November 4, 2021
Alternative Medicine, Other Consumer, Health, Supermarket, Marketing, Food, Beverage, Communications, Agriculture, Natural Resources, Retail, Consumer, Science, Procter & Gamble, USA Today, Kraft Heinz, Danone, TSX Venture Exchange, Knowledge, Greater Toronto Area, Advisory board, Match.com, Wharton School of the University of Pennsylvania, Dairy, Hyundai Capital, USA, Textron, EVP, Future, Forward-looking statement, Marketing, Novartis, Company, UnitedHealth Group, Ageing, Board, Growth, Ticketmaster, Reader's Digest, CNBC, Pitney Bowes, News, Krispy Kreme, LendingTree, IAC, GM, PTI Securities & Futures, CMO, The New York Times, IAC (company), Kraft Foods, FRA, Fine chemical, Risk management, Audit, Future of Cheese, Organic Garage Ltd., FUTURE OF CHEESE, ORGANIC GARAGE LTD.

We are thrilled to have Mr. Heber join our team, commented Jen Wojtaszek, President of Future of Cheese.

Key Points: 
  • We are thrilled to have Mr. Heber join our team, commented Jen Wojtaszek, President of Future of Cheese.
  • For more information please visit the Future of Cheese website at www.futureofcheese.com .
  • The Companys stores are in prime retail locations designed to give customers an inclusive, unique and value-focused grocery shopping experience.
  • Forward-looking statements are not a guarantee of future performance and involve a number of risks and uncertainties, some of which are described herein.

Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer

Retrieved on: 
Thursday, November 4, 2021
Safety, Degenerative disease, Engineering, Entrepreneurship, Lupus, University, Regulation, Lists of diseases, Bio, Industry, Alexion Pharmaceuticals, Failure, Twitter, Family, Rothschild, Security (finance), Wendell Pritchett, U.S. Securities and Exchange Commission, RED, FDA, CRL, Novartis, Company, Risk, Autoimmune disease, Disclosure, CEO, Board, COVID-19, Growth, Celiac, Intercept Pharmaceuticals, Nasdaq, News, Wharton School of the University of Pennsylvania, Education, BANK, Pharmaceutical industry

Andy's strategic vision, collaborative spirit and deeply personal connection to autoimmune disease has played such a crucial role in bringing us to this point in our corporate evolution," stated Ashleigh Palmer, Chief Executive Officer & Co-Founder, Provention Bio.

Key Points: 
  • Andy's strategic vision, collaborative spirit and deeply personal connection to autoimmune disease has played such a crucial role in bringing us to this point in our corporate evolution," stated Ashleigh Palmer, Chief Executive Officer & Co-Founder, Provention Bio.
  • "I would also like to welcome Thierry to the Provention Bio team.
  • I look forward to working together with Thierry to assist him and the Provention team with the transition."
  • Thierry Chauche brings to Provention Bio a broad set of relevant financial experience and a strong track record of success over two decades.

Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand

Retrieved on: 
Wednesday, November 3, 2021
Method, Research, Biotechnology, Technology, Biophysics, Physics, SAN, University, Cancer, Epic Sciences, Industry, Prostate, Genomics, Roswell Park Comprehensive Cancer Center, Texas Tech University, Genetics, Patient, Neoplasm, Company, Lawrence Berkeley National Laboratory, University of California, Eli Lilly and Company, Myriad Genetics, UC, CEO, University of California, Davis, Novartis, Cell biology, Health, CTC, DNA, Epic, Clinical Oncology, Gen-Probe, Clinical Genetics (journal), American Board of Commissioners for Foreign Missions, Physician, ASQ, Pharmaceutical industry, Medical imaging

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Epic Sciences, Inc, developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of delivery experience to the Epic Sciences team.

Key Points: 
  • These three new executives bring a combined 60 plus years of delivery experience to the Epic Sciences team.
  • "I am honored to join Epic Sciences' team," she says.
  • "Joining the Epic Sciences' team to promote commercial growth of cancer testing was an easy decision," says Aguillard.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Global Antibiotic Resistance Markets, 2019-2020 & 2021-2027 - Focus on Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 3, 2021
Health, Pharmaceutical, Market, Research, Sanofi, Novartis, Johnson & Johnson, Investment, Growth, Infection, Awareness, Therapy, Incidence, GlaxoSmithKline, Antibiotics, Pharmaceutical industry, Vaccine, Landscape maintenance

The increase in burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been contributing the global antibiotic resistance market growth over the forecast period.

Key Points: 
  • The increase in burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been contributing the global antibiotic resistance market growth over the forecast period.
  • The increase in incidence of chronic & infectious disease is anticipated to propel the growth of global antibiotic resistance market.
  • Limited number of manufacturers in the field of antibiotic resistance as well as lack of investment from major market players is expected to hamper the global antibiotic resistance market growth during this forecast period.
  • Also, the increase in awareness of individuals about antibiotic resistance in this region, North America & Europe is also contributing the global antibiotic resistance market growth in terms of revenue, due to availability of better medical equipment is propelling the development of antibiotic resistance market in this region.

Nanomedicine Global Market Report 2021: COVID-19 Impact, Growth and Changes to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 2, 2021
Biotechnology, Health, Other Health, Alzheimer's Association, Dementia, Research, Alzheimer's Disease International, Celgene, University of Padua, Amgen, GE Healthcare, Diagnosis, Cardiology, Disease, Nanotechnology, Knowledge, Elective surgery, Cancer, Nanoparticle, Globe, Nanomedicine, Chemistry, Patient, Degenerative disease, University, Novartis, Pfizer, Ablynx, Medicine, Infection, The Department, COVID-19, Growth, Alzheimer's disease, Regenerative medicine, Diabetes, Conditional sentence, Therapy, Carbon, Gilead Sciences, Nanoshell, Pharmaceutical industry, Medical imaging, 3D printing

The "Nanomedicine Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nanomedicine Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the strategists, marketers and senior management with the critical information they need to assess the global nanomedicine market.
  • Nanomedicine is a branch of medicine that applies nanotechnology knowledge and tools for the prevention and treatment of disease.
  • This increasing burden of chronic diseases is expected to propel the demand for effective therapeutics treatment based on nanomedicine, thus driving the market.

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Retrieved on: 
Tuesday, November 2, 2021
Pancreatic cancer, Annual general meeting, Orphan drug, CD39, Research, Cancer, Immunotherapy, Neoplasm, Fast Track, Security (finance), Patient, Walter, D.C, FDA, Private Securities Litigation Reform Act, B cell, CCR8, Risk, Hepatocellular carcinoma, Kidney, Adenosine, Annual report, Forward-looking statement, Novartis, COVID-19, IL-27, CD73, PVRIG, U.S. Securities and Exchange Commission, ATP, GLOBE, SITC, GlaxoSmithKline, Washington Convention Center, Liver, Surface, Tumor microenvironment, Vaccine, Pharmaceutical industry

The posters include preclinical data from Surface Oncologys two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27), both of which are in Phase 1 clinical studies.

Key Points: 
  • The posters include preclinical data from Surface Oncologys two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27), both of which are in Phase 1 clinical studies.
  • Surface scientists will be in attendance on-site in Washington D.C. to present the data.
  • Details are provided below; full posters will be placed on Surface Oncologys website following the presentations.
  • For example, pancreatic cancer stromal cells within the tumor micro-environment express high levels of CD39 which may inhibit anti-cancer immune responses.

Alnylam Named a Science Magazine Top Employer for Third Consecutive Year

Retrieved on: 
Monday, November 1, 2021
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Medication, Â, Biotechnology, LinkedIn, Element, CNS, Twitter, RNA interference, Patient, RNA, Leadership, Nobel Prize, Novartis, Instagram, Nasdaq, Therapy, Central nervous system, Culture, Online shopping, Management, Pharmaceutical industry

Alnylams 2021 ranking marks the third consecutive year that it has placed within the top five on the best employers list.

Key Points: 
  • Alnylams 2021 ranking marks the third consecutive year that it has placed within the top five on the best employers list.
  • Survey respondents rated companies on attributes such as corporate image, leadership and direction, work culture/environment, and academic and intellectual challenge.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
  • For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.